# Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

> **NCT04564001** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 50 (estimated)

## Conditions studied

- Takayasu Arteritis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04564001
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09
- **Primary completion:** 2021-02
- **Final completion:** 2023-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564001, "Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04564001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*